Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14547391 | 0.93 | CYP3A4 (0.43) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 | |
| SCHEMBL2946687 | 0.92 | CYP3A4 (0.46) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 | |
| SCHEMBL2941813 | 0.89 | CYP3A4 (0.40) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 | |
| SCHEMBL3921624 | 0.89 | RORC (0.36) | CYP3A4KCNH2CYP2C9CYP2C19RORC | |
| SCHEMBL2639076 | 0.87 | CYP3A4 (0.42) | CYP3A4 | |
| SCHEMBL2951649 | 0.86 | CYP3A4 (0.39) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 | |
| SCHEMBL3912138 | 0.86 | CYP3A4 (0.38) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 | |
| SCHEMBL2943283 | 0.86 | CYP3A4 (0.38) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 | |
| SCHEMBL2948537 | 0.85 | SLC2A1 (0.43) | CYP3A4SLC2A1MEN1KMT2A | |
| SCHEMBL2638917 | 0.85 | CYP3A4 (0.45) | CYP3A4KCNH2CYP2C9CYP2C19SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940782-B1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-1940782-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007045572-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | claimed |
| US-7754919-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1940782-B1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| EP-1940782-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045572-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, REV1 | CYP3A4 889/4885KCNH2 4150/4885CYP2C9 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.